{"id":{"repo_id":"ncsu","oai_identifier":"oai:repository.lib.ncsu.edu:1840.16/2949"},"canonical_url":"https://search.dev.ndltd.org/etd/ncsu/oai:repository.lib.ncsu.edu:1840.16/2949","repository":{"repo_id":"ncsu","name":"North Carolina State University","base_url":"https://repository.lib.ncsu.edu/server/oai/request"},"display":{"title":"Recombinant Lactobacillus as a Vaccine Vector for HIV","abstract":"The objective of the research was to evaluate the efficacy of Lactobacillus as a vaccine vector against human immunodeficiency virus (HIV) infection. Lactobacillus gasseri, a well characterized commensal of the human intestinal tract, was engineered to express HIV antigens. In this study we have genetically cloned the HIV gag gene into Lactobacillus gasseri, confirmed the expression of Gag protein and evaluated the immunogenicity of the recombinant bacteria in a murine model. To evaluate the immunogenic efficacy of the novel vaccine we have assayed the serum levels of IgG and also mucosal IgA levels (fecal and vaginal washes). Antigen-specific cell mediated immune responses were assessed using IFN-γ ELISPOT, IL-2 ELISPOT and flow cytometric quantification of p24 Gag peptide AMQMLKETI specific CD8+ CD3+ T cells. We also evaluated a prime-boost vaccination strategy where mice were primed with a recombinant p24 Gag intradermally with adjuvant (CpG oligonucleotides) and then boosted orally with recombinant Lactobacillus expressing Gag. The results indicate that prime-boost strategy efficiently elicited anti p24Gag serum IgG levels and mucosal cell mediated immune responses whereas Lactobacillus expressing Gag administered alone was efficient in generating cell mediated immune responses in the intestinal mucosa. Hence lactobacilli have the potential to be a mucosal vaccine delivery vehicle for HIV antigens.","abstract_html":"The objective of the research was to evaluate the efficacy of Lactobacillus as a vaccine vector against human immunodeficiency virus (HIV) infection. Lactobacillus gasseri, a well characterized commensal of the human intestinal tract, was engineered to express HIV antigens. In this study we have genetically cloned the HIV gag gene into Lactobacillus gasseri, confirmed the expression of Gag protein and evaluated the immunogenicity of the recombinant bacteria in a murine model. To evaluate the immunogenic efficacy of the novel vaccine we have assayed the serum levels of IgG and also mucosal IgA levels (fecal and vaginal washes). Antigen-specific cell mediated immune responses were assessed using IFN-γ ELISPOT, IL-2 ELISPOT and flow cytometric quantification of p24 Gag peptide AMQMLKETI specific CD8+ CD3+ T cells. We also evaluated a prime-boost vaccination strategy where mice were primed with a recombinant p24 Gag intradermally with adjuvant (CpG oligonucleotides) and then boosted orally with recombinant Lactobacillus expressing Gag. The results indicate that prime-boost strategy efficiently elicited anti p24Gag serum IgG levels and mucosal cell mediated immune responses whereas Lactobacillus expressing Gag administered alone was efficient in generating cell mediated immune responses in the intestinal mucosa. Hence lactobacilli have the potential to be a mucosal vaccine delivery vehicle for HIV antigens.","abstract_has_math":false,"creators":["Kakarla, Sudha"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Dr Fred J Fuller, Committee Member","Dr Herman F Staats, Committee Member","Dr Gregg A Dean, Committee Chair","Dr Todd R Klaenhammer, Committee Member"],"committee_chairs":[],"committee_members":[],"year":2006,"date_issued":"2006-08-21","date_published":"2006-08-21","updated_at":"2026-08-21T22:21:56Z","subjects":["mice","vaccine vector","gag gene","HIV","Lactobacillus"],"languages":[],"rights":["I hereby certify that, if appropriate, I have obtained and attached hereto a written permission statement from the owner(s) of each third party copyrighted matter to be included in my thesis, dissertation, or project report, allowing distribution as specified below. I certify that the version I submitted is the same as that approved by my advisory committee. I hereby grant to NC State University or its agents the non-exclusive license to archive and make accessible, under the conditions specified below, my thesis, dissertation, or project report in whole or in part in all forms of media, now or hereafter known. I retain all other ownership rights to the copyright of the thesis, dissertation or project report. I also retain the right to use in future works (such as articles or books) all or part of this thesis, dissertation, or project report."],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["etd-08142006-204727"],"render_values":[{"text":"etd-08142006-204727","href":null,"code":true}]}]},"links":{"outbound_url":"http://www.lib.ncsu.edu/resolver/1840.16/2949","outbound_label":"Repository record","outbound_source":"dc:identifier.uri"},"source_record":{"url":"https://repository.lib.ncsu.edu/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Arepository.lib.ncsu.edu%3A1840.16%2F2949","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Dr Fred J Fuller, Committee Member","Dr Herman F Staats, Committee Member","Dr Gregg A Dean, Committee Chair","Dr Todd R Klaenhammer, Committee Member"]},{"key":"dc:creator","label":"Author","values":["Kakarla, Sudha"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2010-04-02T18:19:02Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2010-04-02T18:19:02Z"]},{"key":"dc:date.issued","label":"Date","values":["2006-08-21"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["mice","vaccine vector","gag gene","HIV","Lactobacillus"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights","label":"Dc Rights","values":["I hereby certify that, if appropriate, I have obtained and attached hereto a written permission statement from the owner(s) of each third party copyrighted matter to be included in my thesis, dissertation, or project report, allowing distribution as specified below. I certify that the version I submitted is the same as that approved by my advisory committee. I hereby grant to NC State University or its agents the non-exclusive license to archive and make accessible, under the conditions specified below, my thesis, dissertation, or project report in whole or in part in all forms of media, now or hereafter known. I retain all other ownership rights to the copyright of the thesis, dissertation or project report. I also retain the right to use in future works (such as articles or books) all or part of this thesis, dissertation, or project report."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["etd-08142006-204727"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://www.lib.ncsu.edu/resolver/1840.16/2949"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["North Carolina State University Theses Immunology."]},{"key":"dc:description.abstract","label":"Abstract","values":["The objective of the research was to evaluate the efficacy of Lactobacillus as a vaccine vector against human immunodeficiency virus (HIV) infection. Lactobacillus gasseri, a well characterized commensal of the human intestinal tract, was engineered to express HIV antigens. In this study we have genetically cloned the HIV gag gene into Lactobacillus gasseri, confirmed the expression of Gag protein and evaluated the immunogenicity of the recombinant bacteria in a murine model. To evaluate the immunogenic efficacy of the novel vaccine we have assayed the serum levels of IgG and also mucosal IgA levels (fecal and vaginal washes). Antigen-specific cell mediated immune responses were assessed using IFN-γ ELISPOT, IL-2 ELISPOT and flow cytometric quantification of p24 Gag peptide AMQMLKETI specific CD8+ CD3+ T cells. We also evaluated a prime-boost vaccination strategy where mice were primed with a recombinant p24 Gag intradermally with adjuvant (CpG oligonucleotides) and then boosted orally with recombinant Lactobacillus expressing Gag. The results indicate that prime-boost strategy efficiently elicited anti p24Gag serum IgG levels and mucosal cell mediated immune responses whereas Lactobacillus expressing Gag administered alone was efficient in generating cell mediated immune responses in the intestinal mucosa. Hence lactobacilli have the potential to be a mucosal vaccine delivery vehicle for HIV antigens."]},{"key":"dc:format","label":"Dc Format","values":["Thesis (M.S.)--North Carolina State University."]},{"key":"dc:title","label":"Title","values":["Recombinant Lactobacillus as a Vaccine Vector for HIV"]}]}],"canonical_facts":{"dc:contributor.advisor":["Dr Fred J Fuller, Committee Member","Dr Herman F Staats, Committee Member","Dr Gregg A Dean, Committee Chair","Dr Todd R Klaenhammer, Committee Member"],"dc:creator":["Kakarla, Sudha"],"dc:date.accessioned":["2010-04-02T18:19:02Z"],"dc:date.available":["2010-04-02T18:19:02Z"],"dc:date.issued":["2006-08-21"],"dc:description":["North Carolina State University Theses Immunology."],"dc:description.abstract":["The objective of the research was to evaluate the efficacy of Lactobacillus as a vaccine vector against human immunodeficiency virus (HIV) infection. Lactobacillus gasseri, a well characterized commensal of the human intestinal tract, was engineered to express HIV antigens. In this study we have genetically cloned the HIV gag gene into Lactobacillus gasseri, confirmed the expression of Gag protein and evaluated the immunogenicity of the recombinant bacteria in a murine model. To evaluate the immunogenic efficacy of the novel vaccine we have assayed the serum levels of IgG and also mucosal IgA levels (fecal and vaginal washes). Antigen-specific cell mediated immune responses were assessed using IFN-γ ELISPOT, IL-2 ELISPOT and flow cytometric quantification of p24 Gag peptide AMQMLKETI specific CD8+ CD3+ T cells. We also evaluated a prime-boost vaccination strategy where mice were primed with a recombinant p24 Gag intradermally with adjuvant (CpG oligonucleotides) and then boosted orally with recombinant Lactobacillus expressing Gag. The results indicate that prime-boost strategy efficiently elicited anti p24Gag serum IgG levels and mucosal cell mediated immune responses whereas Lactobacillus expressing Gag administered alone was efficient in generating cell mediated immune responses in the intestinal mucosa. Hence lactobacilli have the potential to be a mucosal vaccine delivery vehicle for HIV antigens."],"dc:format":["Thesis (M.S.)--North Carolina State University."],"dc:identifier.other":["etd-08142006-204727"],"dc:identifier.uri":["http://www.lib.ncsu.edu/resolver/1840.16/2949"],"dc:rights":["I hereby certify that, if appropriate, I have obtained and attached hereto a written permission statement from the owner(s) of each third party copyrighted matter to be included in my thesis, dissertation, or project report, allowing distribution as specified below. I certify that the version I submitted is the same as that approved by my advisory committee. I hereby grant to NC State University or its agents the non-exclusive license to archive and make accessible, under the conditions specified below, my thesis, dissertation, or project report in whole or in part in all forms of media, now or hereafter known. I retain all other ownership rights to the copyright of the thesis, dissertation or project report. I also retain the right to use in future works (such as articles or books) all or part of this thesis, dissertation, or project report."],"dc:subject":["mice","vaccine vector","gag gene","HIV","Lactobacillus"],"dc:title":["Recombinant Lactobacillus as a Vaccine Vector for HIV"]},"updated_at":"2026-08-21T22:21:56Z"}